GlassScriptPhysician profile
Christina Powers
NPI 1073932414
$3,638.51
in general payments reported to CMS, 2019-2025
19 companies · $563 in 2025
The $563 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $249 · 2021: $220 · 2022: $354 · 2023: $728 · 2024: $951 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,241.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $777.84 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $729.32 | 2019-2025 | |
| Lilly USA, LLC | $446.07 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $440.02 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $402.91 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $139.46 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $105.33 | 2020-2025 | Capvaxive, Gardasil 9 |
| Eisai INC. | $94.03 | 2024-2025 | |
| Glaxosmithkline, LLC. | $88.83 | 2023-2024 | Arexvy, Shingrix, Bexsero |
| Exact Sciences Corporation | $83.94 | 2023-2025 | Cologuard Collection Kit |
| Nevro Corp. | $68.20 | 2022 | |
| Amgen INC. | $59.89 | 2019-2020 | |
| Astellas Pharma US INC | $49.21 | 2024 | Veozah |
| Medtronic Vascular, INC. | $39.29 | 2020 | |
| Abbott Laboratories | $32.30 | 2024 | Freestyle Libre 3 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $28.82 | 2021 | |
| Axonics, INC. | $19.82 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.44 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.79 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.